

Publisher: Bentham Science Publishers
E-ISSN: 1875-5828|4|5|503-506
ISSN: 1567-2050
Source: Current Alzheimer Research, Vol.4, Iss.5, 2007-12, pp. : 503-506
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
A number of factors limit the therapeutic application of neurotrophin proteins, such as nerve growth factor (NGF) and brain-derived growth factor (BDNF), for Alzheimer's and other neurodegenerative diseases. These factors include unfavorable pharmacological properties typical of proteins and the pleiotropic effects mediated by protein-ligand interactions with p75NTR, Trk, and sortilin neurotrophin receptors. Targeted modulation of p75NTR provides a strategy for preventing degeneration without promoting TrkA-mediated deleterious effects, and targeted activation of TrkB might achieve more favorable neurotrophic effects than those achieved by concomitant activation of p75NTR and TrkB. The discovery of small molecules functioning as ligands at specific neurotrophin receptors has made possible for the first time approaches for modulating selected components of neurotrophin signaling processes for the purpose of modulating underlying Alzheimer's disease mechanisms.
Related content


Discovery of ADDL-Targeting Small Molecule Drugs for Alzheimer's Disease
Current Alzheimer Research, Vol. 4, Iss. 5, 2007-12 ,pp. :


Neurotrophin Receptor-Based Strategies for Alzheimer's Disease
Current Alzheimer Research, Vol. 2, Iss. 2, 2005-04 ,pp. :






Tau in Alzheimer's Disease: Mechanisms and Therapeutic Strategies
Current Alzheimer Research, Vol. 15, Iss. 3, 2018-01 ,pp. :